JP2022515249A - 癌の治療におけるドセタキセルの長期使用 - Google Patents

癌の治療におけるドセタキセルの長期使用 Download PDF

Info

Publication number
JP2022515249A
JP2022515249A JP2021536409A JP2021536409A JP2022515249A JP 2022515249 A JP2022515249 A JP 2022515249A JP 2021536409 A JP2021536409 A JP 2021536409A JP 2021536409 A JP2021536409 A JP 2021536409A JP 2022515249 A JP2022515249 A JP 2022515249A
Authority
JP
Japan
Prior art keywords
docetaxel
cancer
plasma concentration
treatment
side effects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021536409A
Other languages
English (en)
Japanese (ja)
Inventor
ヘンドリック ベイネン、ジェイコブ
ヘンリクス マティアス シェレンス、ヨハネス
Original Assignee
モドラ ファーマシューティカルズ ビー．ブイ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モドラ ファーマシューティカルズ ビー．ブイ． filed Critical モドラ ファーマシューティカルズ ビー．ブイ．
Publication of JP2022515249A publication Critical patent/JP2022515249A/ja
Priority to JP2023075517A priority Critical patent/JP2023102787A/ja
Priority to JP2025049089A priority patent/JP2025094189A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021536409A 2018-12-21 2019-12-18 癌の治療におけるドセタキセルの長期使用 Pending JP2022515249A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023075517A JP2023102787A (ja) 2018-12-21 2023-05-01 癌の治療におけるドセタキセルの長期使用
JP2025049089A JP2025094189A (ja) 2018-12-21 2025-03-24 癌の治療におけるドセタキセルの長期使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18215472.4 2018-12-21
EP18215472 2018-12-21
PCT/EP2019/086124 WO2020127606A1 (en) 2018-12-21 2019-12-18 Cancer treatment using docetaxel by controlling peak plasma levels

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023075517A Division JP2023102787A (ja) 2018-12-21 2023-05-01 癌の治療におけるドセタキセルの長期使用

Publications (1)

Publication Number Publication Date
JP2022515249A true JP2022515249A (ja) 2022-02-17

Family

ID=64901394

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021536409A Pending JP2022515249A (ja) 2018-12-21 2019-12-18 癌の治療におけるドセタキセルの長期使用
JP2023075517A Pending JP2023102787A (ja) 2018-12-21 2023-05-01 癌の治療におけるドセタキセルの長期使用
JP2025049089A Pending JP2025094189A (ja) 2018-12-21 2025-03-24 癌の治療におけるドセタキセルの長期使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023075517A Pending JP2023102787A (ja) 2018-12-21 2023-05-01 癌の治療におけるドセタキセルの長期使用
JP2025049089A Pending JP2025094189A (ja) 2018-12-21 2025-03-24 癌の治療におけるドセタキセルの長期使用

Country Status (14)

Country Link
US (3) US20220079910A1 (enExample)
EP (2) EP3897610B1 (enExample)
JP (3) JP2022515249A (enExample)
KR (1) KR20220002860A (enExample)
CN (1) CN113543781A (enExample)
AU (2) AU2019410060A1 (enExample)
BR (1) BR112021012255A2 (enExample)
CA (1) CA3124316C (enExample)
CL (1) CL2021001638A1 (enExample)
ES (1) ES3026709T3 (enExample)
IL (1) IL284213A (enExample)
MX (2) MX2021007478A (enExample)
PE (1) PE20220250A1 (enExample)
WO (1) WO2020127606A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023102787A (ja) * 2018-12-21 2023-07-25 モドラ ファーマシューティカルズ ビー．ブイ． 癌の治療におけるドセタキセルの長期使用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20220129A1 (es) * 2018-12-21 2022-01-27 Modra Pharmaceuticals B V Tratamiento de combinacion para tumores solidos usando docetaxel y un inhibidor de cyp3a
GB202201935D0 (en) 2022-02-14 2022-03-30 Modra Pharmaceuticals B V Methods and compositions for treating cancer in taxane-resistant patients

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010536837A (ja) * 2007-08-24 2010-12-02 スティヒティング ヘット ネーデルランド カンケル インスティテュート 組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
KR101544498B1 (ko) * 2007-08-24 2015-08-17 스티칭 허트 네덜란드 칸커 인스티튜트 종양성 질환의 치료를 위한 조성물
US9089544B2 (en) * 2007-08-24 2015-07-28 Slotervaart Participaties Bv Composition
WO2010020799A2 (en) 2008-08-22 2010-02-25 Slotervaart Participaties Bv Composition
EP3897610B1 (en) * 2018-12-21 2025-04-16 Modra Pharmaceuticals B.V. Cancer treatment using docetaxel by controlling peak plasma levels
PE20220129A1 (es) * 2018-12-21 2022-01-27 Modra Pharmaceuticals B V Tratamiento de combinacion para tumores solidos usando docetaxel y un inhibidor de cyp3a

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010536837A (ja) * 2007-08-24 2010-12-02 スティヒティング ヘット ネーデルランド カンケル インスティテュート 組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EUROPEAN JOURNAL OF CANCER, vol. 86, JPN6022026010, 2017, pages 217 - 225, ISSN: 0004961328 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023102787A (ja) * 2018-12-21 2023-07-25 モドラ ファーマシューティカルズ ビー．ブイ． 癌の治療におけるドセタキセルの長期使用

Also Published As

Publication number Publication date
CN113543781A (zh) 2021-10-22
MX2025008270A (es) 2025-08-01
PE20220250A1 (es) 2022-02-16
EP3897610A1 (en) 2021-10-27
KR20220002860A (ko) 2022-01-07
IL284213A (en) 2021-08-31
US20220323399A1 (en) 2022-10-13
JP2025094189A (ja) 2025-06-24
EP3897610B1 (en) 2025-04-16
EP4670718A3 (en) 2026-03-04
US20220079910A1 (en) 2022-03-17
EP4670718A2 (en) 2025-12-31
JP2023102787A (ja) 2023-07-25
CA3124316A1 (en) 2020-06-25
EP3897610C0 (en) 2025-04-16
BR112021012255A2 (pt) 2021-09-28
ES3026709T3 (en) 2025-06-12
US20250312305A1 (en) 2025-10-09
WO2020127606A1 (en) 2020-06-25
CA3124316C (en) 2023-07-04
MX2021007478A (es) 2021-10-13
US11571408B2 (en) 2023-02-07
AU2019410060A1 (en) 2021-08-05
CL2021001638A1 (es) 2022-04-22
AU2023204682A1 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
US20250312305A1 (en) Cancer Treatment Using Docetaxel by Controlling Peak Plasma Levels
US20200246346A1 (en) Combination therapy
JP2025094186A (ja) ドセタキセルおよびｃｙｐ３ａ阻害剤を用いる固形腫瘍の組み合わせ治療
KR20210010524A (ko) 샘낭암종을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조성물
CN114177299A (zh) 包含ezh2抑制剂和scd1抑制剂的抗肿瘤药物组合物及其用途
US20260027117A1 (en) Methods of treating small cell lung cancer
US20220241294A1 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer
EP3302483B1 (en) Pharmaceutical compositions and use thereof
Baas et al. Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer
WO2021228146A1 (zh) 一种lsd1抑制剂的用途
JP2022547702A (ja) 胆管癌の処置のためのパノビノスタットを含む併用療法
US11911374B2 (en) Methods and uses for treating cancer
EP4385507A1 (en) Combination treatment for solid tumors using cabazitaxel and a cyp3a inhibitor
US20250302813A1 (en) Recombinant methioninase in the treatment of cancer
HK40111479A (en) Combination treatment for solid tumors using cabazitaxel and a cyp3a inhibitor
WO2025056747A1 (en) Combination of a wee1 inhibitor and a pkmyt1 inhibitor
CN118946350A (zh) 用于治疗紫杉烷耐药性患者的癌症的方法和组合物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210824

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221121

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230110